



## Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer

April 25, 2018

### Dr. Suri's appointment to senior leadership team adds depth and expertise in immunology and translational studies

CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- [Cue Biopharma](#), Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancer and autoimmune diseases, announced today that Anish Suri, Ph.D. has been appointed as Senior Vice President and Chief Scientific Officer. Dr. Suri, who most recently served as Senior Director of Janssen Immunosciences in Belgium, brings more than 20 years of experience to Cue Biopharma's leadership team with a focus on immuno-oncology, autoimmune disorders, inflammation and translational medicine.

"Having a senior scientific leader with Anish's background and expertise enhances the core strengths of our leadership team and further enables our strategic mission of developing next-generation, precision immunotherapies, offering new hope to patients with serious or life-threatening conditions," said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. "As CSO, Anish brings experienced scientific insight and leadership in essential areas for the next stages of our corporate evolution, including building and leading high-performance, multi-disciplinary teams, executing on research strategies, and driving translational applications that aim to transform our scientific discoveries into innovative medicines and marketable products."

"We look forward to working closely with Anish as we continue to build our translational research and clinical capabilities, including studies of our biologic drug candidates in ex vivo assays from patient clinical samples. With Anish's guidance and oversight, these studies will continue to strengthen our ability to design and conduct biologically and clinically informative Phase I studies," said Kenneth Pienta, M.D., acting Chief Medical Officer of Cue Biopharma.

"I am delighted to join Cue Biopharma and look forward to working with a very talented group of colleagues. They are developing an innovative biologics platform which offers a transformational opportunity for precise immune modulation that ultimately may provide significant benefits to patients. I look forward to guiding and overseeing the discovery and preclinical development activities, and shaping translational research efforts," said Dr. Suri.

Dr. Suri is an immunologist with more than 20 years of experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical Companies, most recently as Senior Director at Janssen Immunosciences. Prior to Janssen, he was responsible for providing strategic guidance to immuno-oncology and immunology drug discovery programs at Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to his work in the pharmaceutical industry, Dr. Suri was Assistant Professor of Pathology and Immunology at Washington University School of Medicine. He received his Ph.D. in immunology from Washington University.

### About Cue Biopharma

Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient's body, with the goal of offering significant therapeutic benefits while potentially minimizing or eliminating unwanted side effects.

We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide switch within previously-validated drug frameworks developed from the Cue Biologics Platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost-efficiently than current industry standard timelines and costs.

Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit [www.cuebio.com](http://www.cuebio.com).

### Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; our ability to secure required U.S. Food and Drug Administration ("FDA")

or other governmental approvals for our product candidates and the breadth of any approved indication; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on licensors, collaborations and strategic alliances; our ability to obtain adequate financing to fund our business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

**Investor Contact:**

John Woolford  
Westwicke Partners  
443-213-0506

**Media Contact:**

Cory Tromblee  
Sam Brown Inc.  
617-571-7220

 [Primary Logo](#)

Source: Cue Biopharma, Inc.